Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity ; volume:20 ; number:1 ; day:7 ; month:10 ; year:2020 ; pages:1-13 ; date:12.2020
Cancer cell international ; 20, Heft 1 (7.10.2020), 1-13, 12.2020
- Creator
-
Zhu, Jialin
Wang, Yan
Li, Dai
Zhang, Haonan
Guo, Zhi
Yang, Xueling
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-020-01583-3
- URN
-
urn:nbn:de:101:1-2020112220245693910102
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhu, Jialin
- Wang, Yan
- Li, Dai
- Zhang, Haonan
- Guo, Zhi
- Yang, Xueling
- SpringerLink (Online service)
Other Objects (12)
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response